Crescita Therpeutc (CTX) AI Stock Analysis

• Market Cap: C$10.86M
• Dividend Yield: N/A
• Average Volume (3M): 9.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.07
• Revenue Growth: -7.56%
• EPS Growth: -334.57%
• Country: CA
• Employees: 80
• Sector: Healthcare
• Sector Strength: 78
• Industry: Pharmaceuticals
• EPS (TTM): -0.14
• Shares Outstanding: 19,050,630
• 10 Day Avg. Volume: 6,944
• 30 Day Avg. Volume: 9,769
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.61
• Price to Cash Flow (P/CF): 6.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Crescita Therapeutics' overall stock score reflects significant challenges in financial performance, particularly in profitability and revenue growth. While the technical analysis shows some positive momentum, the negative valuation metrics weigh heavily. The absence of earnings call insights and corporate events means the focus remains on addressing core financial weaknesses.

Crescita Therpeutc Business Overview & Revenue Model

Company Description

Crescita Therapeutics Inc. (CTX) is a publicly traded, Canadian commercial dermatology company that operates in the life sciences sector. The company focuses on the development and commercialization of non-prescription skincare products and prescription drug products with a primary focus on the treatment of skin conditions. Crescita leverages its patented transdermal delivery technologies to enhance the efficacy of its products.

How the Company Makes Money

Crescita Therapeutics generates revenue through multiple streams, primarily from the sale of its skincare and therapeutic products. The company distributes non-prescription skincare solutions across various retail and online channels, targeting both individual consumers and professional dermatology markets. Additionally, Crescita licenses its proprietary transdermal delivery technologies to other pharmaceutical companies, earning royalties and milestone payments. The company may also engage in partnerships and collaborations with other entities to co-develop and commercialize new therapeutic products, further contributing to its revenue. Crescita's earnings are influenced by its ability to innovate and expand its product portfolio, as well as its strategic alliances within the industry.

Crescita Therpeutc Financial Statement Overview

Summary

Crescita Therapeutic faces significant financial challenges, particularly in terms of profitability and revenue growth. While the balance sheet is stable with low leverage, negative profitability metrics weigh down the overall financial health. Improvements in operational efficiency and profitability are needed.

Income Statement

Crescita Therapeutic's income statement indicates a decline in revenue and profitability. The TTM (Trailing-Twelve-Months) revenue fell slightly compared to the previous year, and the company has experienced negative EBIT and net income margins, suggesting ongoing operational challenges. The revenue growth rate is negative, reflecting a contraction from prior periods.

Balance Sheet

The balance sheet reflects a moderate level of stability with a healthy equity base. Although the debt-to-equity ratio is low, indicating conservative leverage, the return on equity is negative due to recent losses. Despite this, the company maintains a strong equity ratio, highlighting a solid asset base relative to liabilities.

Cash Flow

The cash flow analysis shows a mixed picture. Operating cash flow remains positive, which is a good sign of operational cash generation. However, the free cash flow is negative in the TTM, indicating that capital expenditures may exceed operating cash flow. This could signal potential liquidity challenges if sustained.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
17.40M	17.52M	23.52M	16.77M	15.64M	22.34M
	Gross Profit
8.91M	10.36M	13.18M	10.01M	11.27M	16.54M
	EBIT
-3.06M	-1.96M	732.00K	-529.00K	2.51M	3.97M
	EBITDA
-1.26M	45.00K	2.09M	598.00K	2.26M	5.59M
	Net Income Common Stockholders
-2.74M	-1.99M	862.00K	-1.10M	37.00K	1.85M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.59M	9.38M	8.24M	11.33M	14.28M	9.27M
	Total Assets
27.57M	24.60M	28.48M	28.92M	26.83M	26.84M
	Total Debt
4.41M	1.25M	1.61M	2.87M	1.23M	1.55M
	Net Debt
-4.18M	-8.13M	-6.63M	-8.46M	-13.05M	-7.72M
	Total Liabilities
8.56M	5.78M	7.39M	8.40M	5.70M	5.73M
	Stockholders Equity
19.01M	18.82M	21.10M	20.53M	21.13M	21.11M
Cash Flow		Free Cash Flow
-761.00K	1.94M	-1.25M	-1.94M	5.55M	5.09M
	Operating Cash Flow
1.09M	2.08M	-1.02M	-1.60M	5.61M	5.31M
	Investing Cash Flow
-1.77M	-133.00K	-290.00K	-846.00K	-59.00K	-215.00K
	Financing Cash Flow
-879.00K	-782.00K	-1.85M	-500.00K	-476.00K	-4.39M

Crescita Therpeutc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CTX, the sentiment is Negative. The current price of 0.51 is below the 20-day moving average (MA) of 0.56, below the 50-day MA of 0.57, and below the 200-day MA of 0.57, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.08 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CTX.

Crescita Therpeutc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEO	67 Neutral	C$322.89M	―	-0.53%	5.17%	-21.32%	82.85%
HLS	63 Neutral	C$124.63M	―	-24.49%	―	-8.60%	21.06%
CTX	54 Neutral	C$10.86M	―	-15.57%	―	-7.56%	-334.57%
Sector *	49 Neutral	$6.90B	0.02	-54.05%	2.46%	24.91%	-3.14%
TH	40 Underperform	$100.24M	―		―	6.07%	80.33%

Crescita Therpeutc Corporate Events

Crescita Therapeutics Sees Strong Q3 Revenue Growth

Crescita Therapeutics reported a revenue increase of 18.5% in Q3 2024, driven by growth in its Skincare segment and higher licensing revenue. The company is also enhancing its manufacturing capabilities with new equipment and a long-term agreement with a major client, aiming to boost profitability and secure a new partner for Pliaglis in the U.S.